Skip to content
Surf Wiki
Save to docs
general/alpha-blockers

From Surf Wiki (app.surf) — the open knowledge base

Ifenprodil

Chemical compound


Summary

Chemical compound

FieldValue
Verifiedfieldsverified
verifiedrevid461742484
imageIfenprodil v2.svg
image_classskin-invert-image
tradenameCerocral, Dilvax, Vadilex
classCerebral vasodilators; NMDA receptor antagonists
ATC_prefixC04
ATC_suffixAX28
CAS_number_Ref
CAS_number23210-56-2
PubChem3689
IUPHAR_ligand5472
ChemSpiderID_Ref
ChemSpiderID3561
UNII_Ref
UNIIR8OE3P6O5S
KEGG_Ref
KEGGD08064
ChEBI93829
ChEMBL_Ref
ChEMBL305187
synonymsNP-120; NP 120; NP120; RC 61-91
IUPAC_name4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
C21H=27N=1O=2
SMILESCC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
StdInChI_Ref
StdInChI1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
StdInChIKey_Ref
StdInChIKeyUYNVMODNBIQBMV-UHFFFAOYSA-N

| Drugs.com =

| elimination_half-life =

Ifenprodil, sold under the brand names Cerocral, Dilvax, and Vadilex, is a cerebral vasodilator that has been marketed in some countries, including in Japan, Hong Kong, and France. It is currently under development for treatment of a variety of additional indications.

Ifenprodil has multiple known pharmacological actions. It is an inhibitor of the NMDA receptor, specifically of NMDA receptors containing GluN1 and GluN2B subunits, the "ifenprodil binding site". Additionally, ifenprodil inhibits GIRK channels and interacts with α1-adrenergic, serotonin, and sigma receptors.

Chemically, ifenprodil is a substituted phenethylamine and β-hydroxyamphetamine derivative. It is used pharmaceutically as the tartrate salt.

Research

Ifenprodil has been studied as a possible medication to prevent tinnitus after acoustic trauma.

It is currently in phase II trials for cough and idiopathic pulmonary fibrosis, among other investigational uses.

References

References

  1. (2001). "The Merck Index". Merck Research Laboratories Division of Merck & Co., Inc..
  2. (2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer US.
  3. Schweizerischer Apotheker-Verein. (2004). "Index Nominum: International Drug Directory". Medpharm Scientific Publishers.
  4. (2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Netherlands.
  5. (November 1989). "Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines". Molecular Pharmacology.
  6. (December 2011). "Neurosteroid modulation of N-methyl-D-aspartate receptors: molecular mechanism and behavioral effects". Steroids.
  7. (March 2006). "Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil". Neuropsychopharmacology.
  8. (June 1995). "Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor". Neuropharmacology.
  9. (May 1993). "Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain". European Journal of Pharmacology.
  10. (January 1994). "Further characterization of [3H]ifenprodil binding in rat brain". European Journal of Pharmacology.
  11. (February 1995). "Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors". European Journal of Pharmacology.
  12. (2007). "Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma". Hindawi Limited.
  13. "Ifenprodil - Algernon Pharmaceuticals". Springer Nature Switzerland AG.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about Ifenprodil — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report